OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
33822059

Vuno Inc

Advanced Medical Equipment & TechnologyVerified

Vuno Inc's capital structure shows a debt-to-equity ratio of 0.21, indicating a conservative leverage profile. The company holds 5.55 billion KRW in cash and equivalents but has a negative free cash flow of -5.31 billion KRW, suggesting ongoing operational cash burn. The current ratio of 3.05 implies strong short-term liquidity, though operating cash flow is negative at -4.68 billion KRW. Profitability metrics are weak, with a return on equity of -16% and return on assets of -11.47%. Gross profit of 33.97 billion KRW is high relative to revenue of 34.85 billion KRW, but operating and net losses of -4.93 billion and -5.78 billion KRW, respectively, indicate significant cost overruns or underperformance in converting gross profit to net income. The company's geographic exposure is not explicitly quantified in the input data, but disclosed markets include Japan, Europe, and the United States. Revenue concentration by segment is also not provided, though the product portfolio spans imaging, pathology, biosignal, and voice technologies. The absence of segment-specific revenue data limits visibility into concentration risk. Growth trajectory is unclear due to the lack of historical revenue data, but the current FY outlook is not provided. The company's negative operating and net income suggest a focus on R&D and market expansion rather than immediate profitability. Analysts have assigned a mean recommendation of 1.00 (strong buy), with one strong-buy rating and no buy/hold/sell ratings, indicating optimism about long-term potential despite current losses. Risk factors include medium liquidity risk due to negative free cash flow and operating cash flow, though the current ratio remains strong. Dilution risk is assessed as low, with no near-term pressure indicated. The company's negative net cash position after subtracting total debt raises concerns about its ability to fund operations without external financing. Recent events include a strong-buy analyst rating and a negative EPS actual of -413 KRW compared to a mean estimate of 278 KRW, highlighting the gap between expectations and performance. No recent filings or transcripts are provided in the input data to further contextualize these results.

30-day price · 338220-4200.00 (-26.9%)
Low$11290.00High$19780.00Close$11410.00As of15 May, 00:00 UTC
Profile
CompanyVuno Inc
Ticker338220.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Vuno Inc develops and sells AI-based medical diagnostic and predictive technologies, including imaging, pathology, biosignal, and medical voice products, and sells embolic material Nexpear in domestic and overseas markets.

Classification. Vuno Inc is classified in the Healthcare sector under Advanced Medical Equipment & Technology with 0.92 confidence based on verified market data.

Vuno Inc's capital structure shows a debt-to-equity ratio of 0.21, indicating a conservative leverage profile. The company holds 5.55 billion KRW in cash and equivalents but has a negative free cash flow of -5.31 billion KRW, suggesting ongoing operational cash burn. The current ratio of 3.05 implies strong short-term liquidity, though operating cash flow is negative at -4.68 billion KRW. Profitability metrics are weak, with a return on equity of -16% and return on assets of -11.47%. Gross profit of 33.97 billion KRW is high relative to revenue of 34.85 billion KRW, but operating and net losses of -4.93 billion and -5.78 billion KRW, respectively, indicate significant cost overruns or underperformance in converting gross profit to net income. The company's geographic exposure is not explicitly quantified in the input data, but disclosed markets include Japan, Europe, and the United States. Revenue concentration by segment is also not provided, though the product portfolio spans imaging, pathology, biosignal, and voice technologies. The absence of segment-specific revenue data limits visibility into concentration risk. Growth trajectory is unclear due to the lack of historical revenue data, but the current FY outlook is not provided. The company's negative operating and net income suggest a focus on R&D and market expansion rather than immediate profitability. Analysts have assigned a mean recommendation of 1.00 (strong buy), with one strong-buy rating and no buy/hold/sell ratings, indicating optimism about long-term potential despite current losses. Risk factors include medium liquidity risk due to negative free cash flow and operating cash flow, though the current ratio remains strong. Dilution risk is assessed as low, with no near-term pressure indicated. The company's negative net cash position after subtracting total debt raises concerns about its ability to fund operations without external financing. Recent events include a strong-buy analyst rating and a negative EPS actual of -413 KRW compared to a mean estimate of 278 KRW, highlighting the gap between expectations and performance. No recent filings or transcripts are provided in the input data to further contextualize these results.
Key takeaways
  • Vuno Inc has a conservative debt-to-equity ratio of 0.21 but is burning cash at a rate of -5.31 billion KRW in free cash flow.
  • Gross profit is high at 33.97 billion KRW, but operating and net losses of -4.93 billion and -5.78 billion KRW, respectively, indicate poor cost control or underperformance.
  • Analysts have assigned a strong-buy rating, but the company's negative EPS and cash flow metrics suggest near-term financial challenges.
  • The company's geographic exposure includes Japan, Europe, and the United States, though revenue concentration by region or segment is not disclosed.
  • Liquidity risk is medium, and dilution risk is low, but the negative net cash position raises concerns about funding operations without external capital.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$34.85B
Gross profit$33.97B
Operating income-$4.93B
Net income-$5.78B
R&D
SG&A
D&A
SBC
Operating cash flow-$4.68B
CapEx-$1.07B
Free cash flow-$5.31B
Total assets$50.39B
Total liabilities$14.27B
Total equity$36.11B
Cash & equivalents$5.55B
Long-term debt$7.65B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$36.11B
Net cash-$2.10B
Current ratio3.0
Debt/Equity0.2
ROA-11.5%
ROE-16.0%
Cash conversion81.0%
CapEx/Revenue-3.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 160 companies
Metric338220Activity
Op margin-14.2%-24.0% medp25 -212.9% · p75 6.1%above median
Net margin-16.6%-20.7% medp25 -188.5% · p75 4.8%above median
Gross margin97.5%49.8% medp25 36.6% · p75 67.4%top quartile
CapEx / revenue-3.1%-4.7% medp25 -11.2% · p75 -1.8%above median
Debt / equity21.0%3.6% medp25 0.0% · p75 22.2%above median
Observations
IR observations
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate278.00 KRW
Last actual EPS-413.00 KRW
Mean revenue estimate51,900,000,000 KRW
Last actual revenue34,847,840,000 KRW
Mean EBIT estimate5,100,000,000 KRW
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-15 14:57 UTC#27b7dc77
Source: analysis-pipeline (hybrid)Generated: 2026-05-15 15:01 UTCJob: 9f7ffc2f